The U.S. Food and Drug Administration on Friday granted full approval to Pfizer's elranatamab, sold under the brand name ELREXFIO, for the treatment of relapsed or refractory multiple myeloma in patients who have received at least four prior lines of therapy. The decision converts the drug's accelerated approval — granted in August 2023 — into a full regulatory nod, following confirmatory Phase 3 trial data demonstrating that patients treated with the BCMA-directed bispecific antibody remained largely free from disease progression over extended follow-up periods.

The Phase 3 MagnetisMM-5 trial, whose late-stage results were highlighted in medical and investor circles this week, provided the confirmatory evidence the FDA required. In the study, elranatamab demonstrated a statistically significant improvement in progression-free survival compared to standard physician's choice regimens, with an overall response rate exceeding 58% in the heavily pre-treated population. The depth and durability of response data were described by trial investigators as clinically meaningful in a patient population with very limited remaining options.

Pfizer's oncology division called the full approval a pivotal milestone for patients with multiple myeloma, a blood cancer affecting more than 35,000 Americans annually. 'This confirmation reflects what we have seen consistently — that ELREXFIO offers durable disease control for patients who have exhausted most available therapies,' said a Pfizer oncology spokesperson in a statement released Friday morning. The drug targets BCMA on myeloma cells while engaging CD3 on T-cells, recruiting the immune system to destroy cancer cells.

The approval positions ELREXFIO more firmly against competing BCMA-targeting agents, including Johnson & Johnson's teclistamab (Tecvayli) and Bristol Myers Squibb's ide-cel and cilta-cel CAR-T therapies. Analysts at several investment banks noted that full approval removes a key uncertainty that had constrained some payer formulary decisions, potentially broadening commercial uptake. Pfizer shares edged modestly higher in early Friday trading on the news, with oncology investors watching for any updated pricing or reimbursement guidance.

The FDA's oncology center also noted updated labeling will include the complete Phase 3 dataset and refine guidance on step-up dosing schedules designed to mitigate cytokine release syndrome, one of the drug's primary safety considerations. Patient advocacy groups, including the Multiple Myeloma Research Foundation, welcomed the conversion to full approval as a signal of the FDA's confidence in the drug's benefit-risk profile and called for continued access negotiations with major U.S. insurers to ensure the therapy reaches eligible patients without undue delay.